Ocular Therapeutix, Inc. is a fully-integrated biopharmaceutical company. AXPAXLI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases and conditions of the eye.
Em Crescimento
A empresa está em fase de crescimento, com a receita anual mais recente totalizando US$ 51.95M.
Alto Crescimento de Lucro
O lucro líquido da empresa lidera o setor, com o lucro anual mais recente totalizando US$ 51.95M.
Avaliação Justa
O PE mais recente da empresa é -6.59, em uma faixa percentil média de 3 anos.
Compra Institucional
As participações institucionais mais recentes são de 212.47M ações, um aumento de 5.74% em relação ao trimestre anterior.
Mantido por Steven Cohen
O Super Investidor Steven Cohen possui 5.49M ações desta empresa.